We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+44.61%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$46.6M
Cap. Flow
-$131M
Cap. Flow %
-26.01%
Top 10 Hldgs %
39.38%
Holding
180
New
41
Increased
13
Reduced
50
Closed
76

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.2M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$10.6M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$7.73M
4
SAGE
Sage Therapeutics
SAGE
+$6.1M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$5.3M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$12.7M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$11.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.1M
4
UTHR icon
United Therapeutics
UTHR
+$9.43M
5
CLDX icon
Celldex Therapeutics
CLDX
+$6.76M

Sector Composition

Rank Sector Weight
1 Healthcare 39.26%
2 Consumer Staples 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ENVB icon
126
Enveric Biosciences
ENVB
$6.32M
– –
-25
Closed -$48K
EOLS icon
127
Evolus
EOLS
$385M
– –
-45,516
Closed -$529K
FULC icon
128
CALL
Fulcrum Therapeutics
FULC
$273M
– –
-182,200
Closed -$893K
LKFT
129
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.78B
– –
-86,865
Closed -$4.83M
HEPA
130
DELISTED
Hepion Pharmaceuticals
HEPA
– –
-410
Closed -$235K
HRMY icon
131
Harmony Biosciences
HRMY
$2.04B
– –
-86,035
Closed -$4.2M
IMUX icon
132
Immunic
IMUX
$190M
– –
-6,150
Closed -$214K
IMUX icon
133
PUT
Immunic
IMUX
$190M
– –
-6,150
Closed -$213K
INSM icon
134
Insmed
INSM
$21.4B
– –
-125,000
Closed -$3M
HYFT
135
MindWalk Holdings
HYFT
$60.6M
– –
-61,433
Closed -$237K
IRON icon
136
Disc Medicine
IRON
$2.96B
– –
-14,770
Closed -$749K
ITOS
137
CALL
DELISTED
iTeos Therapeutics
ITOS
– –
-100,000
Closed -$2.06M
KWEB icon
138
KraneShares CSI China Internet ETF
KWEB
$5.64B
– –
-100,000
Closed -$3.28M
KZR
139
CALL
DELISTED
Kezar Life Sciences
KZR
– –
-107,530
Closed -$8.89M
LNTH icon
140
CALL
Lantheus
LNTH
$6.49B
– –
-100,000
Closed -$6.6M
LRMR icon
141
Larimar Therapeutics
LRMR
$397M
– –
-51,606
Closed -$100K
MBIO icon
142
Mustang Bio
MBIO
$4.32M
– –
-329
Closed -$145K
DFTX
143
Definium Therapeutics
DFTX
$5.78B
– –
-7,064
Closed -$68K
MREO
144
Mereo BioPharma
MREO
$54.7M
– –
-615,856
Closed -$199K
MRUS
145
DELISTED
Merus
MRUS
– –
-53,703
Closed -$1.22M
NBIX icon
146
Neurocrine Biosciences
NBIX
$16.8B
– –
-38,600
Closed -$3.76M
NXTC icon
147
NextCure
NXTC
$16.8M
– –
-5,953
Closed -$336K
OVID icon
148
Ovid Therapeutics
OVID
$414M
– –
-26,831
Closed -$59K
PCVX icon
149
Vaxcyte
PCVX
$7.81B
– –
-225,991
Closed -$4.92M
PFE icon
150
Pfizer
PFE
$143B
– –
-80,000
Closed -$4.19M
4 5
6
7 8

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Ikarian Capital held 180 positions worth $502M, down 8.5% from $548M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital withdrew a net $131M in Q3 2022, closing 76 positions and reducing 50 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 43% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Prometheus Biosciences, Inc. Common Stock worth $13.6M.

  • Ikarian Capital's largest Q3 2022 buy was Prometheus Biosciences, Inc. Common Stock: 231,181 shares worth $13.6M.
  • Ikarian Capital added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $12.2M increase.
  • Ikarian Capital's biggest Q3 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $11.1M.
  • Ikarian Capital fully exited Karuna Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $12.7M.
  • Ikarian Capital's ten largest holdings make up 39% of its $502M portfolio in Q3 2022.
  • Ikarian Capital opened 41 new positions and closed 76 in Q3 2022.
  • Ikarian Capital's portfolio value fell 8.5% quarter-over-quarter to $502M.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.